Spark Biomedical Secures Northwell Holdings Investment to Advance OhmBody Menstrual Health Technology

Dallas-based Spark Biomedical announced that Northwell Holdings has made an investment to support development of its OhmBody™ technology, which uses transcutaneous auricular neurostimulation (tAN) to help address menstrual health challenges. The funding will help advance research, development, and commercialization of the wearable neurostimulation device designed to provide a non-invasive, drug-free approach to managing menstruation-related symptoms.

Learn More